- Trial phase
- Phase 1b
- Time to market
- If the pivotal study begins in 2027 as planned, a potential approval would be several years away, likely 2029-2031 assuming positive Phase 3 data and a standard FDA review timeline.
- Why 3/10
- Brezosiran is a Phase 1b asset with no hard dated binary catalyst in the next ~12 months; the next step is a pivotal study planned for 2027 (no specific date), and Alnylam is a large, diversified company with multiple approved products, so brezosiran represents a small fraction of overall value.
The next catalyst for brezosiran is the planned initiation of a placebo-controlled pivotal study in 2027, pending regulatory alignment. Positive Phase 1b data (60-64% mean mHTT reduction) supports advancement, but the drug is still early-stage and represents a small part of Alnylam's diversified, approved-product portfolio. Watch for regulatory feedback and trial design details in 2027.
Price Chart
Executive Summary
Brezosiran (ALN-HTT02) is Alnylam Pharmaceuticals' investigational RNAi therapeutic for Huntington's disease, administered intrathecally using the C16 conjugate platform for CNS delivery. On October 23, 2026, Alnylam reported positive initial Phase 1b data showing mean CSF mutant huntingtin reductions of 60-64% at month 3 (highest dose) with individual reductions up to 83%, and an encouraging safety profile supporting potential twice-yearly dosing. The company plans to initiate a placebo-controlled pivotal study in 2027, pending regulatory alignment. Brezosiran is early-stage (Phase 1b) and represents a small portion of Alnylam's value; the company is a large, diversified RNAi leader with multiple approved products (Amvuttra, Onpattro) that drove $1.3B in Q3 2026 product revenues. ALNY stock fell ~25% on October 29, 2026 due to commercial headwinds for Amvuttra, unrelated to brezosiran.
How It Works
Brezosiran is an RNA interference (RNAi) therapy that uses a short piece of genetic material to 'silence' the huntingtin gene, reducing production of the toxic huntingtin protein that causes Huntington's disease. It is injected into the spinal fluid (intrathecal) to reach the brain, and uses Alnylam's C16 conjugate technology to help the drug enter cells in the central nervous system. It targets exon 1 of the HTT gene, reducing both the full-length mutant huntingtin protein and a shorter toxic fragment called HTT1a.
Trial Status
An ongoing randomized, double-blind, placebo-controlled Phase 1b single ascending dose study in adults with Huntington's disease (HD-ISS Stage 2 or early Stage 3) presented interim data at EHDN October 2026. Initial results showed dose-dependent mHTT reductions with encouraging safety. Alnylam plans to initiate a placebo-controlled pivotal study in 2027 pending regulatory alignment.
The Two-Sided Case
Upcoming Catalysts
- Initiation of placebo-controlled pivotal study in 2027 (date TBD, pending regulatory alignment)
- Regulatory feedback from FDA/EMA on pivotal trial design
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ALNYLAM PHARMACEUTICALS, INC. 8-K ALNY ·Originating report